Article
The anti-IgE mAb omalizumab induces adverse reactions by engaging Fcγ receptors.
The Journal of clinical investigation - 2 Mar 2020
Balbino Bianca, Herviou Pauline, Godon Ophélie, Stackowicz Julien, Goff Odile Richard-Le, Iannascoli Bruno, Sterlin Delphine, Brûlé Sébastien, Millot Gael A, Harris Faith M, Voronina Vera A, Nadeau Kari C, Macdonald Lynn E, Murphy Andrew J, Bruhns Pierre, Reber Laurent L
Abstract excerpt
Omalizumab is an anti-IgE monoclonal antibody (mAb) approved for the treatment of severe asthma and chronic spontaneous urticaria. Use of omalizumab is associated with reported side effects ranging from local skin inflammation at the injection site to systemic anaphylaxis. To date, the mechanisms through which omalizumab induces adverse reactions are still unknown. Here, we demonstrated that immune complexes...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.